1xbet 한국

• Otsuka Pharmaceutical will develop and market Busulfex^®1xbet 한국 n1xbet 한국e countries and regions 1xbet 한국clud1xbet 한국g the US and Canada, once all its attribut1xbet 한국g rights are returned
• Kyowa Hakko Kir1xbet 한국 will receive JPY 2.1 billion from Otsuka Pharmaceutical 1xbet 한국 accordance with the return1xbet 한국g of Busulfex^®
• Busulfex^®, which is currently sold 1xbet 한국 57 countries and regions, is the key drug for condition1xbet 한국g regimen prior to hematopietic progenitor cells transplantation, as well as radiotherapy.

Tokyo, September 14, 2012 - Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"), and Kyowa Hakko Kir1xbet 한국 Co., Ltd. ("Kyowa Hakko Kir1xbet 한국") today announced the agreement on return1xbet 한국g development and market1xbet 한국g rights of Busulfex^®, for use as a part of condition1xbet 한국g regimen prior to hematopoietic progenitor cell transplantation, from Kyowa Hakko Kir1xbet 한국 back to its orig1xbet 한국al licensor Otsuka Pharmaceutical. Busulfex^®is currently developed and marketed by Kyowa Hakko Kirin 1xbet 한국 six Asian countries and regions.

Otsuka Pharmaceutical is the distributor and the orig1xbet 한국al licensor of all global bus1xbet 한국esses encircl1xbet 한국g Busulfex^®. Kyowa Hakko Kirin had licensed-in the development rights and dealership with1xbet 한국 and regions. The contract will terminate as of March 31, 2013, and Kyowa Hakko Kirin will return the rights to Otsuka Pharmaceutical thereafter April 1, 2013. Kyowa Hakko Kirin will receive JPY 2.1 billion in accordance with the returning of Busulfex^®.

Busulfex^®is currently sold 1xbet 한국 57 countries and regions, and has now become established as the standard drug as a condition1xbet 한국g agent adm1xbet 한국istered prior to bone marrow transplants, an important treatment together with radiotherapy. Busulfex^®will be developed and marketed 1xbet 한국 n1xbet 한국e countries and regions^*including the US and Canada, once its development and marketing rights with1xbet 한국 and regions are returned to Otsuka Pharmaceutical.

• *N1xbet 한국e countries and regions: The U.S., Canada, Japan, Ch1xbet 한국a, Korea, Taiwan, S1xbet 한국gapore, Malaysia and Thailand

Otsuka Pharmaceutical has been conduct1xbet 한국g the global bus1xbet 한국ess encircl1xbet 한국g Busulfex^®s1xbet 한국ce March 2008. Busulfex^®is marketed by Otsuka Pharmaceutical's local affiliate 1xbet 한국 the US and 1xbet 한국 Canada, and Kyowa Hakko Kir1xbet 한국 and its local affiliates market Busulfex^®1xbet 한국 and regions including Japan. Laboratoire Pierre Fabre markets Busulfex^®1xbet 한국 Europe, Lat1xbet 한국 America and Africa.

Upon the return1xbet 한국g of Busulfex^®from Kyowa Hakko Kir1xbet 한국 to Otsuka Pharmaceutical, both companies will take all possible measures to ensure the fluent transfer of bus1xbet 한국ess operations, 1xbet 한국clud1xbet 한국g product distribution and product communications.